Physician profile
Donna Booth
NPI 1255339891
$7,907.31
in general payments reported to CMS, 2019-2025
24 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,638 · 2020: $346 · 2021: $458 · 2022: $734 · 2023: $1,257 · 2024: $2,385 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,894 · Travel and Lodging: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,894.49 |
| Travel and Lodging | $836.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,516.00 | 2019-2025 | Lensx, Clareon, Ngenuity |
| Johnson & Johnson Surgical Vision, INC. | $1,822.77 | 2019-2025 | Catalys System, Tecnis Iol, Tecnis Iol |
| Bausch & Lomb Americas INC. | $637.61 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $410.53 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $334.58 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $332.73 | 2019-2023 | |
| Glaukos Corporation | $226.86 | 2019-2025 | Idose, Idosetr |
| Harrow Eye, LLC | $209.22 | 2024-2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $186.42 | 2019-2020 | |
| Oyster Point Pharma, INC. | $156.64 | 2022-2024 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $149.36 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $141.25 | 2019-2022 | |
| Ocular Therapeutix, INC. | $127.09 | 2023 | Dextenza |
| Eyepoint US, INC. | $123.56 | 2022 | |
| Rayner Intraocular Lenses Limited | $120.73 | 2023-2024 | Omidria, Rayone Spheric, Rayone Emv |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $112.55 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Dompe US, INC. | $82.92 | 2021-2025 | Oxervate |
| Allergan, INC. | $79.71 | 2020-2022 | |
| Tearlab Corp | $39.40 | 2019 | |
| Rxsight INC | $32.10 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Johnson & Johnson Vision Care, INC. | $24.11 | 2022 | |
| Horizon Therapeutics Plc | $15.78 | 2019 | |
| Shire North American Group INC | $13.50 | 2019 | |
| Omeros Corporation | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Booth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.